A Clinical Viewpoint on the Use of Targeted Therapy in Advanced Gastric Cancer

Skórzewska, Magdalena; Gęca, Katarzyna; Polkowski, Wojciech P.

doi:10.3390/cancers15225490

Cited by 4 publications

(3 citation statements)

References 176 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This approach encompasses the identification of molecular targets within cancer cells and the subsequent development of drugs designed to block or inhibit these specific targets. The efficacy of targeted therapy surpasses that of traditional chemotherapy (CTH), as it precisely targets cancer cells while sparing normal cells, thereby mitigating potential side effects ( 36 ). However, it comes with an elevated risk of lesion hemorrhage.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Sabaté-Ortega,

Albert-Carrasco,

Escribano-Ferrer

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a kidney neoplasm that accounts for 85% of cases and has complex genetic pathways that affect its development and progression. RCC metastasis can occur in 20%-50% of patients and usually affects distant organs. Gastric metastases (GM) from RCC are rare and present as polyp-like growths in the submucosal layer, accounting for 0.2%-0.7% of cases. This case report describes an 84-year-old female with Furhman grade II ccRCC who presented with an atherothrombotic ischemic stroke and gastrointestinal bleeding nine years post-radical nephrectomy. Gastroscopy revealed a 12mm pseudopedicled gastric lesion with ulceration and bleeding, diagnosed as metastatic ccRCC. The discussion focuses on the rarity, diagnostic challenges, and prognostic elements of gastric metastasis from RCC. The median survival after detecting digestive metastasis varies widely, and the mechanisms include direct invasion and dissemination through lymphatic, transcelomic, or hematogenous routes. Prognostic markers encompass patient history, symptoms, time since RCC diagnosis, overall health, and genetic factors. Surgical removal of gastric lesions and targeted therapy are treatment options that can improve survival. This case report highlights the need for further research to enhance diagnostic and treatment strategies for this rare aspect of RCC pathophysiology.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In cases involving substantial metastases or active bleeding, it becomes imperative to initiate local hemostatic measures before introducing targeted therapy. The management of RCC with gastric metastasis hinges on factors like tumor stage, the extent of metastasis, and patient-specific characteristics ( 36 ).…”

Section: Discussionmentioning

confidence: 99%

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Sabaté-Ortega,

Albert-Carrasco,

Escribano-Ferrer

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Notably, patients eligible for targeted therapy or immunotherapy exhibit significantly higher survival rates overall [ 135 , 136 ]. However, numerous authors highlight the need to refine patient selection for these treatments, enhance drug efficacy, identify new therapeutic targets, and overcome treatment resistance [ 137 , 138 , 139 , 140 ].…”

Section: Gastric Cancer Characterization Prognosis and Management In ...mentioning

confidence: 99%

Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration

Díaz del Arco,

Fernández Aceñero,

Ortega Medina

2024

IJMS

View full text Add to dashboard Cite

Gastric cancer (GC) is a heterogeneous disease, often diagnosed at advanced stages, with a 5-year survival rate of approximately 20%. Despite notable technological advancements in cancer research over the past decades, their impact on GC management and outcomes has been limited. Numerous molecular alterations have been identified in GC, leading to various molecular classifications, such as those developed by The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG). Other authors have proposed alternative perspectives, including immune, proteomic, or epigenetic-based classifications. However, molecular stratification has not yet transitioned into clinical practice for GC, and little attention has been paid to alternative molecular classifications. In this review, we explore diverse molecular classifications in GC from a practical point of view, emphasizing their relationships with clinicopathological factors, prognosis, and therapeutic approaches. We have focused on classifications beyond those of TCGA and the ACRG, which have been less extensively reviewed previously. Additionally, we discuss the challenges that must be overcome to ensure their impact on patient treatment and prognosis. This review aims to serve as a practical framework to understand the molecular landscape of GC, facilitate the development of consensus molecular categories, and guide the design of innovative molecular studies in the field.

show abstract

Efficacy and safety of ramucirumab in gastric or gastroesophageal cancer: A systematic review and meta-analysis

Wu,

Yuan,

Wang

et al. 2024

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

A Clinical Viewpoint on the Use of Targeted Therapy in Advanced Gastric Cancer

Cited by 4 publications

References 176 publications

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration

Efficacy and safety of ramucirumab in gastric or gastroesophageal cancer: A systematic review and meta-analysis

Contact Info

Product

Resources

About